Evidence map›Paper›PMID 42602967›Full record

ArticleiScience2026

Dimitrios Tsallos, Nemo Ikonen, Juho J Miettinen, Muntasir Mamun Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dimitrios TsallosInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Nemo IkonenInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Juho J MiettinenInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Muntasir Mamun MajumderInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Samuli EldforsInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Imre VästrikInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Alun ParsonsInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Minna SuvelaInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Katie DunphyDepartment of Biology, Maynooth University, W23 F2K8 Maynooth, Ireland.
Paul DowlingDepartment of Biology, Maynooth University, W23 F2K8 Maynooth, Ireland.
Despina BazouSchool of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland.
Peter O'GormanDepartment of Haematology, Mater Misericordiae University Hospital, D07 WKW8 Dublin, Ireland.
Juha LievonenDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland.
Raija SilvennoinenDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland.
Pekka AnttilaDepartment of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland.
Caroline A HeckmanInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

del(17p)drug sensitivityhigh-risk genetic abnormalitiesmulti-omic profilingmultiple myelomaprecision oncologytherapeutic vulnerabilitiestp53 mutation

Identifiers

PMID42602967
PMCPMC13475695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.